| Description |
1 online resource (ii, 148 pages) : color illustrations |
|
text txt rdacontent |
|
computer c rdamedia |
|
online resource cr rdacarrier |
| Note |
"February 14, 2019." |
| Bibliography |
Includes bibliographical references. |
| Contents |
Executive summary. -- Introduction. -- 1. China's biotechnology sector. -- 1.1 Current state of China's biotechnology industry by segment. -- 1.2 China's plans and goals for biotechnology. -- 1.3. Comparison of Chinese and US biotechnology programs. -- 1.4 Outlook. -- 2. The role of foreign firms and technologies in China's biotechnology development. -- 2.1 Foreign investment in China. -- 2.2 Chinese outbound investment. -- 2.3 Other channels. -- 2.4 Espionage and other illicit activities. -- 2.5 Regulatory supervision of foreign interaction with Chinese biotech firms and individuals. -- 3. Chinese investment in the US biotechnology industry. -- 3.1 Annual flows and stock. -- 3.2 Entry mode. -- 3.3 Investor mix. -- 3.4 By segments. -- 3.5 US regulation of foreign investment. -- 3.6 Outlook. -- 4. China's involvement in U.S.-based research organizations. -- 4.1 Types of partnerships. -- 4.2 Chinese students and academic research in the US. -- 4.3 Benefits and risks. -- 5. China's access to U.S. healthcare-related data. -- 5.1 Healthcare data and biotechnology. -- 5.2 China's investments in modernizing collection of healthcare data. -- 5.3 Channels of access to US healthcare data. -- 5.4 Data protections and security concerns. -- Conclusions and recommendations. -- Methodology appendix. |
| Summary |
American policymakers have a keen interest in understanding the interaction between the US biotechnology sector and industry developments in China. This high-technology complex is key to economic competitiveness and national security in the years ahead. The US is today the leading biotech nation in the world, a position earned through a century of innovation and healthy market conditions that fostered success. China, meanwhile, is an increasingly important player in biotechnology, given a huge population and effort to advance, and it has great potential to lessen the gap with the US in certain areas. Collaboration with America through investment, education, trade, R & D, and talent flows was critical to China's biotech catch up since the 1980s. The current flow of capital, people, and ideas between the Chinese and US biotech industries reflects the reality of increasing economic globalization that creates benefits to both sides but has recently come under debate given concerns that China's economic, political, and security evolution is not as aligned with American interests as previously assumed. This report reviews the development of China's biotechnology industry and the role foreign trade, investment and other linkages--particularly with the United States--have played in its evolution. We find that integration and collaboration run deep, and that disrupting these linkages would bring high costs for innovation, US welfare and public wealth. Continued investment by the US in its own biotechnology industry will go a long way toward limiting the effectiveness of China's efforts to close the biotechnology gap between the two countries. At the same time, the US needs to address concerns arising from China's current policy directions, including better screening of investment and other engagements for potential national security risks and the protection of sensitive data. |
| Note |
Online resource; title from PDF cover page (USCC, viewed February 18, 2019). |
| Subject |
Biotechnology industries -- China.
|
|
Biotechnology industries -- United States.
|
|
Science and state -- China.
|
|
Investments, Chinese -- United States.
|
|
Intellectual property -- Government policy -- China.
|
|
Investments, American -- China.
|
|
Biotechnology -- Research -- International cooperation.
|
|
Biotechnology industries. (OCoLC)fst00832791
|
|
Intellectual property -- Government policy.
(OCoLC)fst00975779
|
|
Investments, American. (OCoLC)fst00978314
|
|
Investments, Chinese. (OCoLC)fst00978350
|
|
Science and state. (OCoLC)fst01108536
|
|
China. (OCoLC)fst01206073
|
|
United States. (OCoLC)fst01204155
|
| Added Author |
Ritterson, Ryan, author.
|
|
Gardner, Danielle, author.
|
|
Casagrande, Rocco, author.
|
|
Hanemann, Thilo, author.
|
|
Rosen, Daniel H., author.
|
|
U.S.-China Economic and Security Review Commission, issuing body.
|
|
Gryphon Scientific, LLC.
|
|
Rhodium Group.
|
| Running Title |
US role in China's biotechnology development |
| Gpo Item No. |
1089-A-11 (online) |
| Sudoc No. |
Y 3.2:C 44/B 52 |
|
